OSLO/LONDON, May 19th 2021: EXACT THERAPEUTICS AS ("EXACT-Tx" or the "Company"),
a clinical stage precision medicine company utilizing Acoustic Cluster Therapy
(ACT®) across multiple therapeutic areas, today announced that it has been
granted a patent for its innovative Acoustic Cluster Therapy® technology in
Japan. 

The patent covers EXACT-Tx`s unique microbubble/microdroplet formulation and its
use, co-administered with a range of pharmaceutical agents for ultrasound
mediated therapeutic targeting. 

"We are delighted with the decision of the Japanese Patent Office in granting
this important patent for ACT®, which complements the existing patent granted in
China in November 2019. This core patent represents the foundation of our
dynamic IP strategy, which encompasses the use of ACT® with a variety of
therapeutics across a multitude of indications", said Dr Rafiq Hasan, CEO of
EXACT Therapeutics AS. 

About ACT®

o ACT® comprises a proprietary formulation consisting of microbubbles and
microdroplets that is activated through the application of ultrasound with the
consequent increase in targeted delivery of a co-administered therapeutic agent.

o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
o Initial focus of the Company is oncology, however, the ACT® platform has
potential across multiple therapeutic areas (infectious diseases, CNS,
immunotherapy) and classes of therapeutic agents.

About EXACT-Tx

EXACT-Tx is a clinical stage Norwegian biopharmaceutical company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated,
targeted drug enhancement - with the potential to significantly amplify the
clinical utility of a wide range of therapeutic agents across a multitude of
indications including within oncology (chemotherapy, immunotherapy), infectious
diseases, and neurological conditions. www.exact-tx.com



For more information contact:

Dr Rafiq Hasan, CEO EXACT Therapeutics 
Rafiq@exact-tx.com